Tenecteplase is under clinical development by Generium and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase III drugs for Myocardial Infarction have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tenecteplase’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tenecteplase overview

GNR-060 is under development for the treatment of myocardial infarction. It is administered through intravenous bolus route.

Generium overview

Generium is a pharmaceutical company developing novel biological drugs for the treatment of orphan diseases. Generium is headquartered in Moscow, Russia.

For a complete picture of Tenecteplase’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.